We are live on ! Find out more
CODX

Co-Diagnostics
CODX

7 hedge funds and large institutions have $450K invested in Co-Diagnostics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

75% more funds holding

Funds holding: 4 → 7 (+3)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

51% less capital invested

Capital invested by funds: $919K → $450K (-$469K)

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$150K
2
HighTower Advisors
HighTower Advisors
Illinois
+$143K
3
OAM
Oxford Asset Management
United Kingdom
+$52.4K
4
TSS
Two Sigma Securities
New York
+$50.8K
5
TRCT
Tower Research Capital (TRC)
New York
+$8.23K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$308K
2
Morgan Stanley
Morgan Stanley
New York
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
1
HighTower Advisors
Illinois
$265K +$143K +956 +42%
Vanguard Group
2
Vanguard Group
Pennsylvania
$82K +$150K +1,000 New
Millennium Management
3
Millennium Management
New York
$38K -$308K -2,060 -81%
OAM
4
Oxford Asset Management
United Kingdom
$30K +$52.4K +350 New
TSS
5
Two Sigma Securities
New York
$28K +$50.8K +339 New
TRCT
6
Tower Research Capital (TRC)
New York
$5K +$8.23K +55 +500%
UBS Group
7
UBS Group
Switzerland
$2K +$4.64K +31 New
Morgan Stanley
8
Morgan Stanley
New York
– -$10K -51 Closed

CODX Hedge Fund Activity: Q4 2017 in Review

7 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2017, worth a combined $450K — down 51% from $919K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CODX positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $150K. The largest seller was Millennium Management, cutting an estimated $308K.

  • 7 institutional investors held Co-Diagnostics (CODX) as of Q4 2017, up from 4 in Q3 2017.
  • Funds reported $450K of Co-Diagnostics stock for Q4 2017, down 51% quarter-over-quarter.
  • 4 funds opened new Co-Diagnostics positions in Q4 2017 and 1 closed out, a net change of +3 holders.
  • The largest Co-Diagnostics buyer in Q4 2017 was Vanguard Group, an estimated $150K added.
  • The largest Co-Diagnostics seller in Q4 2017 was Millennium Management, an estimated $308K sold.

Based on aggregated 13F filings for Q4 2017.